Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen

Akira Shimada, Yoshiyuki Takahashi, Hideki Muramatsu, Asahito Hama, Olfat Ismael, Atsushi Narita, Hiroshi Sakaguchi, Sayoko Doisaki, Nobuhiro Nishio, Makito Tanaka, Nao Yoshida, Kimikazu Matsumoto, Koji Kato, Nobuhiro Watanabe, Seiji Kojima

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    Fanconi anemia (FA) is a disorder characterized by developmental anomalies, bone marrow failure and a predisposition to malignancy. It has recently been shown that hematopoietic stem cell transplantation using fludarabine (FLU)-based reduced-intensity conditioning is an efficient and quite safe therapeutic modality. We retrospectively analyzed the outcome of bone marrow transplantation (BMT) in eight patients with FA performed in two institutes between 2001 and 2011. There were seven females and one male with a median age at diagnosis = 4.5 years (range 2-12 years). The constitutional characteristics associated with FA, such as developmental anomalies, short stature and skin pigmentation, were absent in three of the patients. One patient showed myelodysplastic features at the time of BMT. All patients received BMT using FLU, cyclophosphamide (CY) and rabbit antithymocyte globulin (ATG) either from a related donor (n = 4) or an unrelated donor (n = 4). Acute graft-versushost disease (GVHD) of grade I developed in one patient, while chronic GVHD was not observed in any patient. All patients are alive and achieved hematopoietic recovery at a median follow-up of 72 months (range 4-117 months). BMT using FLU/low-dose CY/ATG -based regimens regardless to the donor is a beneficial therapeutic approach for FA patients.

    Original languageEnglish
    Pages (from-to)675-679
    Number of pages5
    JournalInternational journal of hematology
    Volume95
    Issue number6
    DOIs
    Publication statusPublished - Jun 1 2012

    Fingerprint

    Fanconi Anemia
    Homologous Transplantation
    Bone Marrow Transplantation
    Antilymphocyte Serum
    Cyclophosphamide
    Tissue Donors
    Skin Pigmentation
    Transplants
    Unrelated Donors
    fludarabine
    Hematopoietic Stem Cell Transplantation
    Bone Marrow
    Rabbits

    All Science Journal Classification (ASJC) codes

    • Hematology

    Cite this

    Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen. / Shimada, Akira; Takahashi, Yoshiyuki; Muramatsu, Hideki; Hama, Asahito; Ismael, Olfat; Narita, Atsushi; Sakaguchi, Hiroshi; Doisaki, Sayoko; Nishio, Nobuhiro; Tanaka, Makito; Yoshida, Nao; Matsumoto, Kimikazu; Kato, Koji; Watanabe, Nobuhiro; Kojima, Seiji.

    In: International journal of hematology, Vol. 95, No. 6, 01.06.2012, p. 675-679.

    Research output: Contribution to journalArticle

    Shimada, A, Takahashi, Y, Muramatsu, H, Hama, A, Ismael, O, Narita, A, Sakaguchi, H, Doisaki, S, Nishio, N, Tanaka, M, Yoshida, N, Matsumoto, K, Kato, K, Watanabe, N & Kojima, S 2012, 'Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen', International journal of hematology, vol. 95, no. 6, pp. 675-679. https://doi.org/10.1007/s12185-012-1079-9
    Shimada, Akira ; Takahashi, Yoshiyuki ; Muramatsu, Hideki ; Hama, Asahito ; Ismael, Olfat ; Narita, Atsushi ; Sakaguchi, Hiroshi ; Doisaki, Sayoko ; Nishio, Nobuhiro ; Tanaka, Makito ; Yoshida, Nao ; Matsumoto, Kimikazu ; Kato, Koji ; Watanabe, Nobuhiro ; Kojima, Seiji. / Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen. In: International journal of hematology. 2012 ; Vol. 95, No. 6. pp. 675-679.
    @article{4e6a78ee462a4f56b56653819c18c3b7,
    title = "Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen",
    abstract = "Fanconi anemia (FA) is a disorder characterized by developmental anomalies, bone marrow failure and a predisposition to malignancy. It has recently been shown that hematopoietic stem cell transplantation using fludarabine (FLU)-based reduced-intensity conditioning is an efficient and quite safe therapeutic modality. We retrospectively analyzed the outcome of bone marrow transplantation (BMT) in eight patients with FA performed in two institutes between 2001 and 2011. There were seven females and one male with a median age at diagnosis = 4.5 years (range 2-12 years). The constitutional characteristics associated with FA, such as developmental anomalies, short stature and skin pigmentation, were absent in three of the patients. One patient showed myelodysplastic features at the time of BMT. All patients received BMT using FLU, cyclophosphamide (CY) and rabbit antithymocyte globulin (ATG) either from a related donor (n = 4) or an unrelated donor (n = 4). Acute graft-versushost disease (GVHD) of grade I developed in one patient, while chronic GVHD was not observed in any patient. All patients are alive and achieved hematopoietic recovery at a median follow-up of 72 months (range 4-117 months). BMT using FLU/low-dose CY/ATG -based regimens regardless to the donor is a beneficial therapeutic approach for FA patients.",
    author = "Akira Shimada and Yoshiyuki Takahashi and Hideki Muramatsu and Asahito Hama and Olfat Ismael and Atsushi Narita and Hiroshi Sakaguchi and Sayoko Doisaki and Nobuhiro Nishio and Makito Tanaka and Nao Yoshida and Kimikazu Matsumoto and Koji Kato and Nobuhiro Watanabe and Seiji Kojima",
    year = "2012",
    month = "6",
    day = "1",
    doi = "10.1007/s12185-012-1079-9",
    language = "English",
    volume = "95",
    pages = "675--679",
    journal = "International Journal of Hematology",
    issn = "0925-5710",
    publisher = "Springer Japan",
    number = "6",

    }

    TY - JOUR

    T1 - Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen

    AU - Shimada, Akira

    AU - Takahashi, Yoshiyuki

    AU - Muramatsu, Hideki

    AU - Hama, Asahito

    AU - Ismael, Olfat

    AU - Narita, Atsushi

    AU - Sakaguchi, Hiroshi

    AU - Doisaki, Sayoko

    AU - Nishio, Nobuhiro

    AU - Tanaka, Makito

    AU - Yoshida, Nao

    AU - Matsumoto, Kimikazu

    AU - Kato, Koji

    AU - Watanabe, Nobuhiro

    AU - Kojima, Seiji

    PY - 2012/6/1

    Y1 - 2012/6/1

    N2 - Fanconi anemia (FA) is a disorder characterized by developmental anomalies, bone marrow failure and a predisposition to malignancy. It has recently been shown that hematopoietic stem cell transplantation using fludarabine (FLU)-based reduced-intensity conditioning is an efficient and quite safe therapeutic modality. We retrospectively analyzed the outcome of bone marrow transplantation (BMT) in eight patients with FA performed in two institutes between 2001 and 2011. There were seven females and one male with a median age at diagnosis = 4.5 years (range 2-12 years). The constitutional characteristics associated with FA, such as developmental anomalies, short stature and skin pigmentation, were absent in three of the patients. One patient showed myelodysplastic features at the time of BMT. All patients received BMT using FLU, cyclophosphamide (CY) and rabbit antithymocyte globulin (ATG) either from a related donor (n = 4) or an unrelated donor (n = 4). Acute graft-versushost disease (GVHD) of grade I developed in one patient, while chronic GVHD was not observed in any patient. All patients are alive and achieved hematopoietic recovery at a median follow-up of 72 months (range 4-117 months). BMT using FLU/low-dose CY/ATG -based regimens regardless to the donor is a beneficial therapeutic approach for FA patients.

    AB - Fanconi anemia (FA) is a disorder characterized by developmental anomalies, bone marrow failure and a predisposition to malignancy. It has recently been shown that hematopoietic stem cell transplantation using fludarabine (FLU)-based reduced-intensity conditioning is an efficient and quite safe therapeutic modality. We retrospectively analyzed the outcome of bone marrow transplantation (BMT) in eight patients with FA performed in two institutes between 2001 and 2011. There were seven females and one male with a median age at diagnosis = 4.5 years (range 2-12 years). The constitutional characteristics associated with FA, such as developmental anomalies, short stature and skin pigmentation, were absent in three of the patients. One patient showed myelodysplastic features at the time of BMT. All patients received BMT using FLU, cyclophosphamide (CY) and rabbit antithymocyte globulin (ATG) either from a related donor (n = 4) or an unrelated donor (n = 4). Acute graft-versushost disease (GVHD) of grade I developed in one patient, while chronic GVHD was not observed in any patient. All patients are alive and achieved hematopoietic recovery at a median follow-up of 72 months (range 4-117 months). BMT using FLU/low-dose CY/ATG -based regimens regardless to the donor is a beneficial therapeutic approach for FA patients.

    UR - http://www.scopus.com/inward/record.url?scp=84864984364&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84864984364&partnerID=8YFLogxK

    U2 - 10.1007/s12185-012-1079-9

    DO - 10.1007/s12185-012-1079-9

    M3 - Article

    C2 - 22527854

    AN - SCOPUS:84864984364

    VL - 95

    SP - 675

    EP - 679

    JO - International Journal of Hematology

    JF - International Journal of Hematology

    SN - 0925-5710

    IS - 6

    ER -